UK Infinity, Post-Market Clinical Follow-up Study

Status Active, not recruiting

Clinical Trial Summary

Clinical Trial Description

Study Title UK Post-Market Clinical Follow-Up Of The INFINITY® Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System N Subjects 500 with 10 sites Follow-Up Schedule Subject enrollment will consist of a Pre-operative, Operative, 6 months, 1 yr., 2 yr., 5yr., 7 yr., 10 yr., and an unscheduled visit as needed. Primary Objective Evaluate the long-term survivorship of the INFINITY® implant over 10 years Secondary Objective(s) Secondary objectives assessed will be to: - Identify and assess the implant for component loosening and/or subsidence, any osteolysis and/or cyst formation through radiographic evaluation early and throughout the lifetime of the implant. - Compare the improvements in self-reported pain and social interaction for quality of life measures from pre-op through 10 years post operatively; assessed by EuroQol (EQ5D5L). - Compare pain and functional improvement in the Ankle Osteoarthritis Score (AOS), which is a visual analogue scale specifically designed as a modification of the Foot Function Index. - Compare the improvement in self-reported pain-free function scores from pre-op through 10 years post-operatively, assessed by the Manchester Oxford Foot Questionnaire (MOXFQ) walking/standing scores. - Identify and report the safety of the implant in terms of complications and adverse events. Inclusion Criteria Subjects to be included in the study must meet all of the following criteria: - Be 21 years of age at the time of surgery; - Diagnosed with unilateral and/or bilateral ankle joint disease; - Diagnosed with ankle joint damage from rheumatoid arthritis, post-traumatic, or degenerative arthritis; Willing and able to consent to participate (written, informed consent / witnessed verbal consent) Willing and able to attend the requested follow-up visits; - Subjects determined by the Investigator to be an appropriate candidate for the INFINITY® Total Ankle System Exclusion Criteria Subjects will be excluded from the study if they meet any of the following criteria: - Subjects with an ankle condition, as determined by the investigator, to be an inappropriate candidate for a total ankle replacement; - Subjects requiring revision total ankle replacement of the ankle being considered for study ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03063593
Study type	Observational
Source	Stryker Trauma GmbH
Contact
Status	Active, not recruiting
Phase
Start date	April 29, 2016
Completion date	December 31, 2029

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01682512` - Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis	Phase 3
Completed	`NCT00539760` - A Phase I Rheumatoid Arthritis Study in Healthy Volunteers	Phase 1
Active, not recruiting	`NCT03312465` - Anatomical Shoulder Domelock System Study
Completed	`NCT01208181` - A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)	Phase 3
Completed	`NCT03254810` - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects	Phase 1
Completed	`NCT01711814` - A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	Phase 2
Completed	`NCT03315494` - Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers	Phase 1
Withdrawn	`NCT03241446` - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)	Phase 1
Completed	`NCT02553018` - Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe	Phase 3
Completed	`NCT02748785` - MTX Discontinuation and Vaccine Response	Phase 4
Active, not recruiting	`NCT02260778` - Treat-to-target in RA: Collaboration To Improve adOption and adhereNce	N/A
Completed	`NCT02569736` - Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Completed	`NCT01750931` - This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.	Phase 2
Withdrawn	`NCT01204138` - Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA	Phase 2
Not yet recruiting	`NCT01154647` - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes	N/A
Completed	`NCT00913458` - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis	Phase 4
Completed	`NCT00975130` - Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)	Phase 3
Completed	`NCT00973479` - An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy	Phase 3
Completed	`NCT00660647` - Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)	Phase 3
Completed	`NCT00550446` - A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis	Phase 2